Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NanoCellect Biomedical

Explore full profile

A critical element for biomedical research is the ability to analyze and isolate cells using flow cytometers

San Diego, United StatesFounded 2009Biotech & Life Sciences
Valuation $100–250M Last recorded · 2023
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for NanoCellect Biomedical and the history behind them.

About NanoCellect Biomedical

NanoCellect Biomedical Inc. is a life sciences company focused on developing and commercializing advanced cell sorting technologies. The company was founded in 2009 by José Morachis, Will Alaynick, and Sung Hwan Cho. The founders' collective expertise in engineering, molecular biology, and business from their time at the University of California, San Diego, provided the foundation for the company's core technology. Their journey began with the recognition of a significant unmet need in the research community for a gentler, more accessible, and affordable cell sorter that could handle sensitive cells without causing damage.

The company operates in the cell analysis market, serving researchers in academic institutions, biotechnology, and pharmaceutical companies. Its business model revolves around the sale of its proprietary instruments, consumables, and software. Revenue is generated through the direct sale of these products and recurring income from the single-use microfluidic cartridges required for the system's operation.

NanoCellect's flagship product is the WOLF Cell Sorter, which utilizes a microfluidic-based, sterile, and disposable cartridge system. This design distinguishes it from traditional fluorescence-activated cell sorters (FACS) by providing a gentle sorting mechanism that minimizes stress on cells, thereby improving cell viability and preserving their integrity. The WOLF is a benchtop instrument known for its ease of use, requiring minimal training to operate. It is capable of sorting and dispensing single cells into 96-well or 384-well plates, making it particularly suitable for applications such as single-cell genomics, antibody discovery, and cell line development. The system avoids the complex fluidics and high pressures of traditional sorters, eliminating the need for dedicated operators and extensive cleanup procedures. Another key product, the N1 Single-Cell Dispenser, complements the WOLF by enabling precise dispensing of single cells for downstream analysis.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2009
Headquarters
San Diego, United States
Employees
31
Open positions
None listed
Dealroom signal
62.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Accounting, Testing, Verification, Biotechnology, Spinout, Biotech and Pharma, medical testing, DT and LS, science-based
Technology
Hardware
Business model
Manufacturing
Client focus
b2b

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jun 2023 $29M $116M Undisclosed ↗
GRANTOther financing Jan 2022 $0 — Undisclosed —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

NanoCellect Biomedical website traffic

Latest recorded traffic for NanoCellect Biomedical is 10K monthly website visits, down 9.1% over the last three months. NanoCellect Biomedical's team declined 18.4% over the past year.

Latest monthly visits10K 3-month web change-9.1% 1-year team growth-18.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Illumina Ventures
  • Anzu Partners
  • Vertical Venture Partners
  • Genoa Ventures
  • FusionX Ventures
  • Highlander Venture Fund

Series B and later5 investors entered at this stage

Other known investors1 additional known investor

  • University of California, San Diego
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States92.9%
🇱🇧 Lebanon3.6%
🇮🇹 Italy3.6%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NanoCellect Biomedical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NanoCellect Biomedical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.